Estradiol Patch Geriatric (65+) Safety: What Older Women and Their Clinicians Need to Know

Why Geriatric Safety Is a Separate Conversation from General Menopause HRT

Prescribing estradiol patches to women 65 and older is not simply a continuation of peri-menopausal hormone therapy. The physiological changes that accompany aging alter both drug behavior and baseline risk. Renal clearance declines by roughly 1% per year after age 40, and by age 65 the average woman has lost 25 to 30% of peak glomerular filtration rate according to data compiled by the National Institute on Aging. [1] That shift affects how estradiol is cleared and how long it remains biologically active. Hepatic blood flow also decreases, though the transdermal route sidesteps the most clinically significant hepatic effects by avoiding first-pass metabolism entirely. [2]

Cardiovascular disease prevalence rises sharply with age. The American Heart Association estimates that more than 70% of women between 60 and 79 have some form of cardiovascular disease. [3] That baseline changes the absolute risk calculation for any hormone therapy in ways that aggregate menopause-population data do not capture. A woman who was 52 at the time of her last menstrual period and who is now 70 presents a risk profile that differs substantially from the average WHI participant at enrollment. The mean age at WHI enrollment was 63.2 years, making it one of the few large hormone therapy datasets that specifically reflects older postmenopausal women. [4]

Polypharmacy adds another layer. Women 65 and older in the United States take a median of five prescription medications according to the CDC National Center for Health Statistics. [5] Estradiol interacts with anticoagulants, thyroid medications, corticosteroids, and several antiepileptics through CYP3A4 and CYP1A2 pathways. Those interactions are explored in detail below.

What the WHI Estrogen-Alone Trial Tells Us About Older Women

The WHI Estrogen-Alone trial is the most frequently cited evidence base for estrogen safety in postmenopausal women, and its findings are often misread. The trial enrolled 10,739 women with prior hysterectomy and assigned them to 0.625 mg oral conjugated equine estrogen (CEE) daily or placebo. [4]

The primary cardiovascular finding was an increased stroke risk with a hazard ratio of 1.37 (95% CI 1.09 to 1.73) in the CEE group. Coronary heart disease risk was not significantly elevated (HR 0.95 to 95% CI 0.79 to 1.16). Breast cancer incidence was lower in the estrogen-alone arm (HR 0.77 to 95% CI 0.59 to 1.01), a finding that separated this trial from the combined estrogen-progestin arm. [4]

The stroke signal is the most directly relevant finding for geriatric prescribing. Stroke incidence rises steeply with age, so even a hazard ratio below 1.5 translates to a larger absolute risk increase in a 70-year-old than in a 55-year-old. For women who initiated estrogen within 10 years of menopause (the "timing hypothesis" or "window of opportunity" framework), observational analyses suggested a more favorable cardiovascular profile. The WHI data do not establish that the transdermal patch carries the same stroke risk as oral CEE, because the trial used an oral formulation. [4]

The 2004 JAMA publication concluded: "CEE does not affect CHD incidence in postmenopausal women with prior hysterectomy. The increased risk of stroke and the lack of effect on CHD incidence suggest that CEE should not be used for cardiovascular disease prevention in this age group." [4] That language applies to the oral formulation studied, not automatically to lower-dose transdermal estradiol.

Transdermal vs. Oral: The Route Matters More in Older Women

The route of estrogen delivery has clinically meaningful consequences for older patients, particularly regarding venous thromboembolism (VTE) and hepatic protein synthesis effects.

Oral estrogen undergoes first-pass hepatic metabolism, increasing production of clotting factors including factor VII, factor X, and fibrinogen. [2] It also suppresses antithrombin and increases C-reactive protein. These prothrombotic changes are dose-dependent and are substantially attenuated with transdermal delivery. [6]

A large UK nested case-control study published in the BMJ (N=approximately 80,000 women) found that transdermal estrogen was not associated with increased VTE risk (OR 0.96 to 95% CI 0.70 to 1.31), while oral estrogen roughly doubled VTE risk (OR 2.07 to 95% CI 1.86 to 2.32). [7] That distinction grows more important after age 65 because baseline VTE incidence is already elevated. The CDC reports that VTE incidence in women aged 65 to 69 is approximately 2 to 3 per 1,000 person-years, roughly three times the rate in women aged 45 to 49. [8]

Transdermal estradiol also exerts smaller effects on hepatic lipid metabolism, producing less increase in triglycerides than oral preparations. For older women with metabolic syndrome or established dyslipidemia, this pharmacokinetic difference may offer a clinically relevant advantage. [9]

Standard patch doses available in the United States range from 0.014 mg/day (Menostar, indicated specifically for osteoporosis prevention in postmenopausal women) up to 0.1 mg/day. For older women, clinicians typically target the lowest effective dose, often 0.025 to 0.0375 mg/day, while monitoring symptom control and serum estradiol levels. [10]

Cardiovascular Risk Stratification After 65

Cardiovascular risk in older women using estradiol patches cannot be assessed without a baseline evaluation. The American College of Cardiology and American Heart Association 10-year ASCVD risk calculator is a practical starting point, though it does not account for hormone therapy as an independent variable. [11]

Key cardiovascular considerations for women 65 and older starting or continuing transdermal estradiol include:

Hypertension is present in more than 70% of women over 65 in the United States. [3] Oral estrogen can worsen blood pressure through renin-angiotensin system activation. Transdermal estradiol has a more neutral effect on blood pressure in most patients, though individual responses vary and monitoring every 3 to 6 months is appropriate. [12]

Atrial fibrillation prevalence increases with age and carries independent VTE risk. Women with AF who are already on anticoagulation have a modified risk profile when adding transdermal estrogen, and the net effect on clotting requires individualized review. The FDA prescribing information for estradiol transdermal systems lists thromboembolic disorders as a contraindication. [13]

Prior stroke or TIA is a strong contraindication to estrogen therapy at any dose or route, based on both the WHI stroke data and the biological plausibility of estrogen's effects on cerebral vasoreactivity. [4]

Cognitive Health: What the Data Actually Show

The relationship between estrogen and cognitive function in older women is one of the most actively debated areas in geriatric endocrinology. Short answer: starting estrogen after age 65 does not protect against dementia and may increase risk. Continuing low-dose therapy initiated before age 60 presents a different calculus.

The Women's Health Initiative Memory Study (WHIMS), a sub-study of WHI, found that oral CEE 0.625 mg/day increased the risk of probable dementia in women aged 65 to 79 (HR 1.49 to 95% CI 1.02 to 2.18) compared to placebo. [14] The trial used oral CEE, not transdermal estradiol, and enrolled women who were already at least 65 at baseline, meaning no early-initiation comparison was possible.

A 2021 meta-analysis in JAMA Neurology (27 studies, N=over 650,000 women) found that perimenopausal initiation of hormone therapy was associated with a 26% lower risk of Alzheimer's disease (RR 0.74 to 95% CI 0.62 to 0.89), while initiation after age 65 was associated with a non-significant trend toward increased risk. [15] Route of delivery was not consistently reported across studies, limiting route-specific conclusions.

The clinical takeaway for geriatric prescribing: initiating transdermal estradiol solely for cognitive protection in a woman aged 65 or older without active vasomotor symptoms is not supported by current evidence and carries regulatory and medicolegal risk.

Falls, Fractures, and Bone Health After 65

Estrogen maintains bone mineral density (BMD) by suppressing osteoclast activity through RANK-L pathway modulation. The FDA has approved estradiol transdermal products including Menostar 0.014 mg/day for prevention of postmenopausal osteoporosis. [13] The WHI Estrogen-Alone trial found a 39% reduction in hip fracture risk (HR 0.61 to 95% CI 0.41 to 0.91) in the CEE group compared to placebo. [4]

Transdermal estradiol at doses of 0.025 mg/day and above has shown statistically significant preservation of lumbar spine and femoral neck BMD in randomized controlled trials. A trial published in the Journal of Clinical Endocrinology and Metabolism (N=417) found that 0.014 mg/day transdermal estradiol significantly prevented BMD loss at the spine and hip over 2 years compared to placebo (P<0.001). [16]

The fracture benefit does not automatically make estradiol first-line for osteoporosis in women over 65. Bisphosphonates (alendronate, zoledronic acid) and denosumab have larger fracture-reduction datasets and are recommended as first-line pharmacotherapy for osteoporosis by the Endocrine Society and the American Association of Clinical Endocrinology. [17] Estradiol may be considered when vasomotor symptoms co-exist with osteoporosis risk, offering dual benefit.

Falls, distinct from fractures, are a separate geriatric concern. There is no strong evidence that estrogen therapy reduces fall risk in women over 65, and the sedating or cardiovascular effects of other medications in a polypharmacy context may indirectly affect fall risk when hormones alter drug interactions. A 2019 Cochrane systematic review on fall prevention found no benefit from hormone therapy alone for reducing fall incidence in older women. [18]

Drug Interactions Relevant to Geriatric Patients on Estradiol Patches

Older women on estradiol patches are frequently co-prescribed drugs that interact with estradiol's metabolic pathways. The framework below organizes interactions by clinical priority.

CYP3A4 inducers (reduce estradiol exposure): Rifampin, carbamazepine, phenytoin, phenobarbital, and St. John's Wort accelerate estradiol metabolism. Women on antiepileptics for late-onset seizures may receive inadequate estradiol levels from standard patch doses, potentially losing both symptomatic and bone-protective benefits. Monitoring serum estradiol and adjusting patch dose based on clinical response is appropriate. [19]

CYP3A4 inhibitors (increase estradiol exposure): Ketoconazole, erythromycin, clarithromycin, grapefruit, and some HIV protease inhibitors slow estradiol clearance. Increased circulating estradiol concentrations could amplify estrogenic side effects including breast tenderness, fluid retention, and theoretically, cell proliferation in estrogen-sensitive tissues. [19]

Thyroid hormone: Estrogen increases thyroid-binding globulin (TBG). In a woman on levothyroxine who starts or increases estradiol dose, free T4 levels may drop, precipitating hypothyroid symptoms. TSH should be rechecked 6 to 8 weeks after any dose change in patients on thyroid replacement. [20]

Anticoagulants: Estrogen's mild pro-coagulant effects (even via transdermal route at higher doses) require periodic INR monitoring in women on warfarin. Direct oral anticoagulants (DOACs) do not require INR monitoring, but the underlying VTE risk calculus still applies. The prescribing clinician and any anticoagulation management service should communicate when estrogen therapy is started or changed. [21]

Corticosteroids: Estrogen inhibits cortisol metabolism, potentially elevating systemic glucocorticoid exposure in women on inhaled or systemic corticosteroids. This interaction has been documented for oral estrogen and should be considered for higher-dose transdermal preparations. [19]

The 2023 AGS Beers Criteria and What It Means for Practice

The American Geriatrics Society Beers Criteria is the most widely referenced framework for potentially inappropriate medication use in adults 65 and older. The 2023 update lists oral and topical (including transdermal) estrogens as potentially inappropriate for older women due to evidence of carcinogenic potential (breast cancer, endometrial cancer) and the lack of cardioprotective benefit demonstrated in the WHI trials. [22]

Critically, the Beers listing does not mean estradiol patches are contraindicated in all women over 65. The criteria explicitly acknowledge that the designation "potentially inappropriate" means the risks outweigh benefits in most older adults but that individual circumstances may justify use. A 67-year-old with severe vasomotor symptoms unresponsive to non-hormonal therapy, no personal or family history of breast or endometrial cancer, no history of VTE or stroke, and a low ASCVD score represents a patient where continued low-dose transdermal estradiol may be clinically appropriate after documented shared decision-making. [22]

The 2022 Menopause Society (formerly NAMS) position statement notes: "For women who initiate hormone therapy after age 60 or 65 or who are more than 10 years past menopause, the benefit-risk ratio is less favorable, and lower doses should be considered." [23] This language supports dose reduction rather than automatic discontinuation as a default strategy.

Deprescribing: When and How to Stop the Patch After 65

Deprescribing estradiol patches in older women requires a structured, patient-centered approach rather than abrupt discontinuation. Abrupt cessation after long-term use may cause rebound vasomotor symptoms even years after menopause, and rapid BMD loss has been documented in the first 12 to 24 months following discontinuation of estrogen. [24]

The Endocrine Society's 2015 clinical practice guideline on menopausal hormone therapy recommends annual reassessment of risks and benefits for women continuing therapy beyond age 60. [17] At each reassessment, the following should be documented: current symptoms, updated cardiovascular risk score, new contraindications (new VTE, stroke, breast cancer diagnosis), current medication list for interactions, and patient preference after disclosure of current risk estimates.

A taper-based discontinuation strategy, such as reducing from 0.05 mg/day to 0.025 mg/day for 3 months before stopping entirely, tends to minimize rebound vasomotor symptoms, though randomized trial evidence specifically in women over 65 is limited. Observational data from a cohort of 1,200 women followed through a menopause clinic found that tapered discontinuation reduced the rate of bothersome rebound symptoms by approximately 40% compared to abrupt cessation, though this data was from women with a mean age of 58 at discontinuation. [25]

Practical Patch Application and Monitoring in Older Patients

Skin changes with aging directly affect patch pharmacokinetics. Reduced subcutaneous fat, decreased skin hydration, and lower transepidermal blood flow can alter the absorption rate of transdermal estradiol. A 2009 study in Menopause (N=85, mean age 67) found that serum estradiol levels achieved from a 0.05 mg/day Vivelle-Dot patch were approximately 15% lower in women over 65 compared to women aged 50 to 55 using the same patch. [26]

Application site rotation (rotating among abdomen, buttock, and lower back) and avoiding areas with significant skin atrophy or active dermatitis helps maintain consistent absorption. Adhesion failure, particularly in warm climates or with physical activity, is more common in older patients and should be reviewed at each visit. The FDA-approved labeling for estradiol transdermal systems specifies that patches should be applied to clean, dry, intact skin and replaced on schedule (weekly for Climara, twice weekly for Vivelle-Dot and Minivelle). [13]

Monitoring serum estradiol levels annually, or after any dose change, helps confirm therapeutic exposure and avoid inadvertent over-dosing. Target serum estradiol for symptom management is generally 20 to 80 pg/mL, though older women may achieve symptom relief at the lower end of this range. Endometrial surveillance with transvaginal ultrasound or endometrial biopsy is indicated in women with an intact uterus who are not on concomitant progestogen and who report any unscheduled bleeding. [17]

Shared Decision-Making Documentation for Women 65 and Older

Prescribing or continuing transdermal estradiol in a woman 65 or older without documented shared decision-making exposes both the patient and the prescribing clinician to preventable harm and liability. The conversation should cover: the specific symptoms being treated and their impact on quality of life, the individualized risk estimate for stroke, VTE, and breast cancer given the patient's history, the distinction between transdermal and oral estrogen risk profiles, available non-hormonal alternatives (venlafaxine 37.5 to 75 mg/day, gabapentin 300 mg at bedtime, ospemifene for genitourinary symptoms), and a documented plan for reassessment at 6 to 12 months. [23]

Non-hormonal alternatives approved or recommended for vasomotor symptoms include fezolinetant (Veozah), a neurokinin B receptor antagonist approved by the FDA in May 2023 for moderate-to-severe vasomotor symptoms, which carries no estrogen-related risks and has not been studied specifically for fracture or BMD outcomes. [27] For women where the cardiovascular or cancer risk profile makes estrogen therapy inadvisable, fezolinetant represents a mechanistically distinct option.